Concert Pharmaceuticals Inc logo

CNCE - Concert Pharmaceuticals Inc Share Price

$4.02 -0.0  -0.9%

Last Trade - 2:46pm

Small Cap
Market Cap £94.4m
Enterprise Value £11.1m
Revenue £5.72m
Position in Universe 5082nd / 6927
Unlock CNCE Revenue
Relative Strength (%)
1m +3.36%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -70.0%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
66.7 0.17 143.9 10.5 1.08 7.90 1.80 10.4 -34.7%
Balance Sheet
FINANCIAL BRIEF: : For the three months ended 31 March 2021, ConcertPharmaceuticals Inc revenues decreased 29% to $5K. Net lossincreased 11% to $22.7M. Revenues reflect a decrease indemand for the Company's products and services due tounfavorable market conditions. Higher net loss reflectsResearch & Development exp increase of 31% to $16.6M(expense), Stock-based Compensation in R&D increase of 47%to $1.9M (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History


CNCE Revenue Unlock CNCE Revenue

Net Income

CNCE Net Income Unlock CNCE Revenue

Normalised EPS

CNCE Normalised EPS Unlock CNCE Revenue

PE Ratio Range

CNCE PE Ratio Range Unlock CNCE Revenue

Dividend Yield Range

CNCE Dividend Yield Range Unlock CNCE Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
CNCE EPS Forecasts Unlock CNCE Revenue
Profile Summary

Concert Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drugs. The Company operates through the development of pharmaceutical products on its own behalf or in collaboration with others. The Company's deuterated chemical entity platform (DCE Platform), has potential across various therapeutic areas. Its product candidates include AVP-786, CTP-656, CTP-730, CTP-543 and JZP-386. The Company's product candidate, CTP-656, is a next generation potentiator that it is initially developing for the treatment of cystic fibrosis in patients having gating mutations, including the G551D mutation. CTP-543 was discovered by applying Concert's deuterium chemistry technology to modify ruxolitinib. AVP-786 is a combination of a dextromethorphan and an ultra-low dose of quinidine. CTP-730 is a phosphodiesterase 4 (PDE4) inhibitor that has potential for the treatment of various inflammatory diseases.

Last Annual December 31st, 2020
Last Interim March 31st, 2021
Incorporated April 12, 2006
Public Since February 13, 2014
No. of Shareholders: 12
No. of Employees: 71
Sector Healthcare
Industry Biotechnology & Medical Research
Index Nasdaq Composite ,
Exchange NASDAQ Global Market
Shares in Issue 32,173,778
Free Float (0.0%)
Eligible for
CNCE Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for CNCE
Upcoming Events for CNCE
Wednesday 4th August, 2021 Estimate
Q2 2021 Concert Pharmaceuticals Inc Earnings Release
Wednesday 3rd November, 2021 Estimate
Q3 2021 Concert Pharmaceuticals Inc Earnings Release
Frequently Asked Questions for Concert Pharmaceuticals Inc
What is the Concert Pharmaceuticals Inc share price?

As of 2:46pm, shares in Concert Pharmaceuticals Inc are trading at $4.02, giving the company a market capitalisation of £94.4m. This share price information is delayed by 15 minutes.

How has the Concert Pharmaceuticals Inc share price performed this year?

Shares in Concert Pharmaceuticals Inc are currently trading at $4.02 and the price has moved by -59.82% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Concert Pharmaceuticals Inc price has moved by -70.52% over the past year.

What are the analyst and broker recommendations for Concert Pharmaceuticals Inc?

Of the analysts with advisory recommendations for Concert Pharmaceuticals Inc, there are there are currently 1 "buy" , 0 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Concert Pharmaceuticals Inc is Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will Concert Pharmaceuticals Inc next release its financial results?

Concert Pharmaceuticals Inc is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2022-03-31
What is the Concert Pharmaceuticals Inc dividend yield?

Concert Pharmaceuticals Inc does not currently pay a dividend.

Does Concert Pharmaceuticals Inc pay a dividend?

Concert Pharmaceuticals Inc does not currently pay a dividend.

When does Concert Pharmaceuticals Inc next pay dividends?

Concert Pharmaceuticals Inc does not currently pay a dividend.

How do I buy Concert Pharmaceuticals Inc shares?

To buy shares in Concert Pharmaceuticals Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Concert Pharmaceuticals Inc?

Shares in Concert Pharmaceuticals Inc are currently trading at $4.02, giving the company a market capitalisation of £94.4m.

Where are Concert Pharmaceuticals Inc shares listed? Where are Concert Pharmaceuticals Inc shares listed?

Here are the trading details for Concert Pharmaceuticals Inc:

Country of listing: United States
Exchange: NMQ
Ticker Symbol: CNCE
What kind of share is Concert Pharmaceuticals Inc?

Based on an overall assessment of its quality, value and momentum, Concert Pharmaceuticals Inc is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Concert Pharmaceuticals Inc share price forecast 2021?

Shares in Concert Pharmaceuticals Inc are currently priced at $4.02. At that level they are trading at 0.279% discount to the analyst consensus target price of 0.00.

Analysts covering Concert Pharmaceuticals Inc currently have a consensus Earnings Per Share (EPS) forecast of -2.923 for the next financial year.

How can I tell whether the Concert Pharmaceuticals Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Concert Pharmaceuticals Inc. Over the past six months, the relative strength of its shares against the market has been -70.97%. At the current price of $4.02, shares in Concert Pharmaceuticals Inc are trading at -51.03% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Concert Pharmaceuticals Inc PE Ratio?

We were not able to find PE ratio data for Concert Pharmaceuticals Inc.

Who are the key directors of Concert Pharmaceuticals Inc?

Concert Pharmaceuticals Inc's management team is headed by:

Richard Aldrich - NEC
Roger Tung - PRE
Nancy Stuart - COO
Ronald Barrett - IND
Peter Hutt - IND
Wilfred Jaeger - IND
Thomas Auchincloss - IND
James Cassella - OTH
Marc Becker - CFO
Jesper Hoiland - IND
Jeffrey Munsie - SEC
Who are the major shareholders of Concert Pharmaceuticals Inc?

Here are the top five shareholders of Concert Pharmaceuticals Inc based on the size of their shareholding:

RA Capital Management, LP Hedge Fund
Percentage owned: 9.43% (3.03m shares)
Perceptive Advisors LLC Private Equity
Percentage owned: 6.68% (2.15m shares)
BlackRock Institutional Trust Company, N.A. Investment Advisor
Percentage owned: 6.57% (2.12m shares)
Ingalls & Snyder LLC (Asset Management) Investment Advisor/Hedge Fund
Percentage owned: 4.52% (1.45m shares)
The Vanguard Group, Inc. Investment Advisor/Hedge Fund
Percentage owned: 4.32% (1.39m shares)
Similar to CNCE
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.